By THE PULSE NEWS MEXICO STAFF
Mexico’s long-promised Patria vaccine against covid19 infections, announced as an emergency measure by President Andrés Manuel López Obrador (AMLO) in the spring of 2020, is nowhere close to getting into people’s arms.
According to government sources, the vaccine is currently in phase 2 testing — there are five requires testing stages for a vaccine’s approval — but this stage has been stalled because of an initial rejections of about 75 percent of test candidates due to low antibody rates.
The vaccine, which is being developed at the National Council for Science and Technology (Conacyt), was commissioned by the president in April 2020, and was due to be ready for human applications by the end of 2021 for administration throughout the country, following the beginning of volunteer-based human trials.
Conacyt has provided little information since then, and it is still unknown if the medication will be administered intramuscularly or intranasally.
The proposed vaccine, which would be 100 percent Mexican, would combine two technologies developed in the United States with the intention of satisfying the global demand for a low-cost vaccine against covid-19.
One of these technologies was developed by the University of Texas at Austin. It is a HexaPro protein, a modified version of the SARS-CoV-2 spike protein with six strategic alterations in its molecular structure that produce a more stable and resistant protein.
On the other hand, the Avimex laboratory, the one chosen by Conacyt to develop the Patria project, uses the exclusive license to use the rNDV platform in Mexico for the development of vaccines against Covid-19 from the Icahn School of Medicine in Mount Sinai. (NY).
The rNDV platform has also served as the basis for the development of other vaccine projects against the SARS-CoV-2 virus in other countries such as Brazil, Vietnam and Thailand. In the case of Brazil, according to reports from the Butantan Institute, it is a vaccine with the most promising results as a single vaccine against covid-19 and the flu, but it is still in the preliminary study phase, with clinical studies expected to be carried out next year.